Antimetabolites in Cancer Therapy

Anticancer Therapeutics

Volumn , Issue , 2008, Pages 91-110

  Scaife, Jessica ^a   Kerr, David ^b  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antimetabolites haematological malignancy therapeutic mainstay; Cancer therapy antimetabolites; Capecitabine monotherapy; Doxifluridine oral prodrug; Folate antagonists; Methotrexate and routine pharmacokinetic monitoring; NICE (national institute for clinical excellence) guidelines and dukes' C carcinoma; Normal biochemical reaction metabolites; Pyrimidine antagonists

Indexed keywords

EID: 84889284540     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470697047.ch7     Document Type: Chapter

References (24)

1. Food and Drug Administration Professional Drug Information. Fluorouracil. http://www.drugs.com/ppa/fluorouracil.html
2. Food and Drug Administration Professional Drug Information. Methotrexate. Mylan Pharmaceuticals Inc. 2004a. http://www.drugs.com/pro/methotrexate.html
3. Food and Drug Administration Professional Drug Information. Mercaptopurine. Mylan Pharmaceuticals Inc. 2004b. http://www.drugs.com/pro/mercaptopurine.html
4. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007, 25(21), 3069-75.
5. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006, 24(9), 1395-403.
6. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007, 25(4), 424-30.
7. Krug LM, Azzoli CG, Kris MG, et al. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003, 9(6), 2072-8.
8. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006, 24(13), 2059-64.
9. Lennon AM, Mulcahy MD, Hyland JMP, et al. Peritoneal involvement in stage II colon cancer. Am J Clin Pathol 2003, 119, 108-13.
10. National Institute for Clinical Excellence. The use of gemcitabine for the treatment of pancreatic cancer. Technology Appraisal No. 25. NICE, London, 2001a. www.nice.org.uk
11. National Institute for Clinical Excellence. Fludarabine for the treatment of B-cell chronic lymphocytic leukaemia. Technology Appraisal No. 29. NICE, London, 2001b. www.nice.org.uk
12. National Institute for Clinical Excellence. Improving outcomes in breast cancer. Cancer service guidance. NICE, London, 2002. www.nice.org.uk
13. National Institute for Clinical Excellence. Capecitabine and tegafur uracil for metastatic colorectal cancer. Technology appraisal No. 61. NICE, London, 2003a. www.nice.org.uk
14. National Institute for Clinical Excellence. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. Technology Appraisal No. 61. NICE, London, 2003b. www.nice.org.uk
15. National Institute for Clinical Excellence. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer. Technology Appraisal No. 62. NICE, London, 2003c. www.nice.org.uk
16. National Institute for Clinical Excellence. Improving outcomes in colorectal cancer. Cancer service guidance. NICE, London, 2004. www.nice.org.uk
17. National Institute for Clinical Excellence. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review). Technology Appraisal No. 93. NICE, London, 2005a. www.nice.org.uk
18. National Institute for Clinical Excellence. Lung cancer: diagnosis and treatment. Clinical guideline No. 24. NICE, London, 2005b. www.nice.org.uk
19. National Institute for Clinical Excellence. Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer. Technology Appraisal No. 100. NICE, London, 2006. www.nice.org.uk
20. National Institute for Clinical Excellence. Permetrexed for the treatment of non-small-cell lung cancer. Technology Appraisal No. 124. NICE, London, 2007a. www.nice.org.uk
21. National Institute for Clinical Excellence. Gemcitabine for the treatment of metastatic breast cancer. Technology Appraisal No. 116. NICE, London, 2007b. www.nice.org.uk
22. National Institute for Clinical Excellence. Permetrexed disodium for the treatment of malignant pleural mesothelioma. Technology Appraisal No. 135. NICE, London, 2008. www.nice.org.uk
23. Peterson VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002, 51, 65-9.
24. van Meerbeeck JP, Gaafar R, Manegold C, et al.: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28), 6881-9.